Company profile: Indigo BioAutomation
1.1 - Company Overview
Company description
- Provider of automated data analysis, management, and integration solutions for clinical and life science laboratories, including ASCENT for LC-MS/MS workflows and ARQ for PCR data. Offers vendor-neutral SaaS platforms with machine learning/AI, a quality rule system applying lab SOPs across instruments, and hosted access from anywhere for flexible, efficient operations.
Products and services
- Advanced Algorithms: Machine-learning-driven components that analyze complex clinical and life science data sets, directly improving diagnostic testing outcomes and overall operational efficiency in laboratory environments
- ASCENT: SaaS-based platform for LC-MS/MS workflows that automates data analysis, integrates with laboratory SOPs, streamlines operations, and reduces manual review times
- ARQ: SOP-integrated SaaS platform for PCR instrument data that automates data analysis and streamlines workflows, integrating with laboratory SOPs to enhance operational efficiency in molecular diagnostics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Indigo BioAutomation
Metagenomi
HQ: United States
Website
- Description: Provider of an AI- and metagenomics-driven discovery platform to uncover novel genome editing systems for therapeutics development and a comprehensive gene editing toolbox, including programmable nucleases, base editors, RNA- and DNA-mediated integration systems, ultra-small systems deliverable via single AAV for organ targeting, and RNA Mediated Integration Systems for small and large programmable genomic edits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Metagenomi company profile →
Nucleai
HQ: United States
Website
- Description: Provider of an AI-powered spatial biology platform designed to enhance drug development and improve patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nucleai company profile →
PatientIQ
HQ: United States
Website
- Description: Provider of a cloud-based patient outcomes platform for healthcare providers, industry partners, and researchers. Integrates with major EHRs to automate patient-reported data collection from diagnosis to recovery. Delivers biostatistical analytics for benchmarking, predictive modeling, and visualizations, patient engagement tools, eCRF/ePRO electronic data capture, and registry participation and compliance workflows.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PatientIQ company profile →
Massive Bio
HQ: United States
Website
- Description: Provider of an AI-powered oncology platform that connects cancer patients to clinical trials and enables pharma to access patients. Offers SYNERGY-AI clinical trial matching, AskFiona and DrArturo AI chatbots, telehealth consultations, genomics analysis for personalized treatment, and concierge services to help patients navigate care and trial options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Massive Bio company profile →
Immunai
HQ: United States
Website
- Description: Provider of immunology mapping and reprogramming solutions leveraging machine learning and software engineering, including AMICA—a comprehensive immune cell knowledge base integrating clinico-genomic data; single-cell analysis and functional genomics; and drug discovery and development support from target discovery and validation through compound validation and clinical trial optimization, with biopharma and academic partnerships contributing data back to AMICA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunai company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Indigo BioAutomation
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Indigo BioAutomation
2.2 - Growth funds investing in similar companies to Indigo BioAutomation
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Indigo BioAutomation
4.2 - Public trading comparable groups for Indigo BioAutomation
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →